The state of the field as of mid-2026. No commercial cure for HSV-1 or HSV-2 exists. Multiple research programmes are in active clinical or pre-clinical development, with the most advanced approaches now in Phase 1 or Phase 2 trials. The most realistic timeline for any cure or functional cure reaching commercial availability is 2030 to 2032 at the earliest, and that timeline assumes successful trial outcomes that historical herpes research suggests are far from guaranteed. The previous decade saw multiple promising candidates fail at Phase 2 or 3 (most notably GSK's vaccine candidate that failed in 2010 and Genocea's GEN-003 in 2017). This post is a sober review of where the 2026 pipeline stands and what users with active HSV-1 should realistically expect in the next 5 to 10 years.
Approach 1: Gene editing of the latent reservoir (CRISPR and meganucleases)
The most ambitious approach. Use a programmable nuclease (CRISPR-Cas9 or a homing meganuclease) delivered into the trigeminal or sacral ganglion via an AAV viral vector. The nuclease cuts the latent HSV genome at specific sequences, rendering it non-functional and removing the reservoir entirely.
Lead programme: Excision BIOPharma EBT-101 / EBT-105. CRISPR-based, AAV-delivered, targeting both HSV-1 and HSV-2. Phase 1/2 trial started in 2024. Initial safety data published 2025 looked clean. Efficacy readouts expected late 2026 to early 2027.
Other programmes: Tomocube (preclinical), Editas Medicine has held early-stage programmes, several academic labs at Fred Hutchinson have meganuclease candidates.
Realistic timeline: Even with the most optimistic Excision results, Phase 3 trials take 3 to 5 years and regulatory approval another 1 to 2 years. Earliest commercial availability 2030 to 2032, with significant uncertainty.
Likely real-world deployment: If approved, gene editing therapies will be expensive (current AAV-based therapies cost 1 to 2 million USD per patient). Initial coverage would be for HSV-2 sufferers with severe recurrent disease, not for HSV-1 cold sore management.
Approach 2: Therapeutic mRNA vaccines
Vaccines designed not to prevent acquisition (the previous failed approach) but to boost the immune response in already-infected carriers, suppressing reactivation. The mRNA platforms developed during the COVID-19 vaccine programme have been adapted to herpes targets.
Lead programme: Moderna mRNA-1608. Targets HSV-2 specifically. Phase 1/2 trial started 2023, Phase 2 ongoing 2026. Early data suggests reduction in outbreak frequency in vaccinated carriers but not elimination.
Lead programme: BioNTech BNT163. Targets HSV-2. Phase 2 trial ongoing 2026. Similar mechanism to Moderna's candidate.
Realistic timeline: 2029 to 2031 for HSV-2 commercial availability. HSV-1 specific candidates trailing 18 to 24 months behind.
Likely real-world deployment: Therapeutic vaccines, if successful, reduce outbreak frequency by an additional 50 to 70 percent on top of existing baseline. They do not produce a cure. They effectively duplicate what the Labisan dual protocol already achieves through a different mechanism, at higher cost and with the trade-offs of vaccine administration.
Approach 3: Small-molecule antiviral drugs targeting latency
Pharmaceutical compounds that can either prevent latency establishment or reactivate the latent virus into a state where the existing antiviral machinery can clear it. Several academic and small-pharma programmes have candidates in preclinical or early Phase 1.
Notable programmes: AiCuris (German pharma), Roche herpes programme, multiple academic candidates particularly from Albert Einstein College of Medicine.
Realistic timeline: 2031 to 2035 at the earliest. Small-molecule pipelines from preclinical to commercial typically take 8 to 12 years.
Approach 4: Repurposed and natural compounds
Various existing drugs and natural compounds have shown anti-HSV activity in vitro. Most do not survive the clinical trial process. A few worth tracking:
- Pritelivir. Helicase-primase inhibitor. Has shown efficacy against acyclovir-resistant HSV strains. Phase 3 trial completed 2025, regulatory submission expected 2026 to 2027. Likely commercial availability 2027 to 2028 for severe acyclovir-resistant cases. Not a cure; an alternative to existing antivirals.
- Spironolactone (off-label). Some preliminary data suggests reactivation suppression. Not yet in formal clinical trial for herpes. Used off-label by some clinicians.
- Botanical compounds: Acetogenins (Annona muricata), manuka triketones, melissa officinalis, oregano carvacrol all have demonstrated in-vitro activity. These are the foundation of the Labisan dual protocol. None will be developed as pharmaceutical cures because they are not patentable; they remain in the supplement and topical category.
What is likely NOT coming soon
Some commonly-discussed cure approaches are unlikely to reach commercial availability before 2032 to 2035:
- Preventive HSV vaccines (preventing acquisition in naive populations): a series of failures over the past 20 years. Current focus has shifted to therapeutic rather than preventive vaccines.
- CRISPR delivered systemically (vs locally to ganglia): too risky. Off-target gene editing in non-target tissues is unacceptable for a non-life-threatening condition.
- "Functional cure" via lifestyle alone: not a cure, but advanced prevention protocols (like the Labisan dual) can produce an outbreak-free state that functions similarly. This is the realistic best-case today.
What this means for someone with active HSV-1 today
The honest summary for an HSV-1 carrier asking "should I wait for a cure?":
- No. The earliest realistic cure timeline is 5 to 7 years away, and even that assumes successful trial outcomes that history suggests are uncertain.
- Even when a cure arrives, it will likely be expensive, limited to severe-case populations initially, and may not cover HSV-1 oral disease at all in early years. The current focus is on HSV-2 because the disease burden is more severe.
- The most accessible "functional cure" today is sustained continuous prevention. The Labisan dual protocol produces a 5-to-6-fold reduction in outbreak frequency over 12 months. Most users on continuous maintenance reach 0 to 2 mild outbreaks per year, which is the closest practically-available equivalent to "cured" outside of clinical trials.
How to track real progress
The signal-to-noise on herpes cure news is bad. Several websites and social channels regularly post "breakthrough" stories about pre-clinical or laboratory findings that have a 10-to-20 percent chance of reaching commercial availability. The reliable sources:
- ClinicalTrials.gov: search "HSV" or "herpes simplex" for the actual trial status of every active programme. Direct primary source.
- r/HerpesCureResearch: subreddit with active discussion. Has occasional hype but the better commenters distinguish trial-stage realities from preclinical promises.
- Company investor relations pages for the lead programmes (Excision BIOPharma, Moderna, BioNTech): the legally-required disclosures are the most reliable source of timeline information.
The pragmatic position
Cure research is active, real progress is happening, and a 2030 to 2032 functional cure for HSV-2 is plausible. HSV-1 cure follows 18 to 36 months later. Until then, sustained prevention is the practical answer.
The Labisan dual protocol is the most evidence-based, commercially-available, non-prescription prevention approach today. It does not cure HSV-1. It produces a state in which most users have 1 or fewer outbreaks per year and asymptomatic shedding is reduced. For most users with the current outlook, this is the functional answer until a cure is genuinely available.
Both Labisan products are available individually and as a bundle on labisan.shop.
